

# Sulfur Dioxide: a Novel Gaseous Signal in the Regulation of Cardiovascular Functions

D. Liu<sup>1</sup>, H. Jin<sup>1</sup>, C. Tang<sup>\*,2,3</sup> and J. Du<sup>\*,1,3</sup>

<sup>1</sup>Department of Pediatrics, Peking University First Hospital, Beijing, 100034, China

<sup>2</sup>Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, 100191, China

<sup>3</sup>Key Laboratory of Molecular Cardiology, Ministry of Education, Beijing, China

**Abstract:** The atmospheric pollutant sulfur dioxide (SO<sub>2</sub>) is endogenously generated from the normal metabolism of sulfur-containing amino acids through the aspartate aminotransferase pathway. SO<sub>2</sub> is produced in cardiovascular tissues, and the aspartate aminotransferase mRNA is localized in endothelia and in vascular smooth muscle cells near the endothelial layer. Recent studies explored the physiological and pathophysiological effects of endogenous SO<sub>2</sub> on the cardiovascular system, and various potential mechanisms were found. These discoveries suggest a novel role of endogenous SO<sub>2</sub> in the modulation of the cardiovascular system and provide a basis for new treatments for cardiovascular diseases.

**Keywords:** Cardiovascular, gaseous signal, sulfur dioxide, pathophysiology, physiology, toxicology.

## INTRODUCTION

Sulfur dioxide (SO<sub>2</sub>) is a colourless dense gas that smells pungent. It enters the atmosphere primarily from anthropogenic activities, such as the combustion of coal and residual fuel oil. Hydrogen sulfide (H<sub>2</sub>S), derived from the eruptions of volcanoes and the biological decay of organic matter, is rapidly oxidized to SO<sub>2</sub> when entering the atmosphere. The reduction of sulfate is another source of sulfur in nature [1]. The biogeochemical sulfur cycle comprises all of the sulfur compounds. SO<sub>2</sub> is a major member of this cycle and plays a critical role in maintaining the balance of environmental sulfur [2]. As a well-known pollutant gas, SO<sub>2</sub> is involved in the formation of photochemical smog and acid rain, both of which are harmful to humans, animals and plants [1]. However, SO<sub>2</sub> is widely used in the manufacture of food, wine and cosmetics as an antimicrobial agent or antioxidant [2].

Balazy *et al.* speculated that SO<sub>2</sub> might be a type of endothelium-derived hyperpolarizing factor (EDHF) because it shares several features with EDHFs [3]. As well, SO<sub>2</sub> is generated endogenously from sulfur-containing amino acids (SAAs) [4]. Researchers have therefore focused on the physiological functions of SO<sub>2</sub> other than the only environmental influences or industrial uses, particularly the regulatory effects on the cardiovascular system.

The aim of this review is to (i) describe the endogenous generation and metabolism of SO<sub>2</sub>, (ii) briefly summarize the toxicological effects of SO<sub>2</sub>, and (iii) give an overview of the physiological and pathophysiological significance of endogenous SO<sub>2</sub> in the cardiovascular system.

## ENDOGENOUS GENERATION AND METABOLISM OF SO<sub>2</sub>

SO<sub>2</sub> can be produced from the normal metabolism of SAAs [5]. Five types of SAAs are present in the human body: methionine (Met), cysteine (Cys), cystine, homocysteine and taurine. In mammals, Met is an essential amino acid, whereas Cys is considered a semi-essential amino acid because it can be converted from homocysteine and serine *via* trans-sulfuration, and its sulfur stems from Met sulfur indirectly [5, 6]. Cys can also be supplied in the diet [5].

*L*-Cys is a vital precursor for the endogenous synthesis of SO<sub>2</sub> [5,7]. *L*-Cys is oxidized to *L*-cysteinesulfinate catalyzed by cysteine dioxygenase (CDO) and then *L*-cysteinesulfinate is transaminated to form  $\beta$ -sulfinylpyruvate catalyzed by aspartate aminotransferase (AAT) [5,7]. The metabolite  $\beta$ -sulfinylpyruvate decomposes spontaneously to pyruvate and SO<sub>2</sub> [7]. Some of the SO<sub>2</sub> is hydrated to sulfite, which is subsequently oxidized by sulfite oxidase to sulfate, and the latter is excreted into the urine [8]; but some SO<sub>2</sub> can exist in the gaseous form, thus evading this reaction [3]. Another pathway for *L*-cysteinesulfinate metabolism involves *L*-cysteinesulfinate being decarboxylated by cysteinesulfinate decarboxylase (CSD) to carbon dioxide (CO<sub>2</sub>) and hypotaurine. Most of the latter is subsequently oxidized to taurine [5,7]. The 2 pathways compete with each other [7]. Griffith, by researching the inhibitor of CSD, found that the activities of AAT and CSD determined the reaction tendency of *L*-cysteinesulfinate [9]. Some sulfate is activated to form 3'-phosphoadenosine-5'-phosphosulfate (PAPS), which serves as a sulfate donor endogenously [5]. H<sub>2</sub>S, metabolized from SAAs catalyzed by cystathionine  $\beta$ -synthase (CBS) or cystathionine  $\gamma$ -lyase (CSE) [10], can also be converted into SO<sub>2</sub> derivatives, such as thiosulfate, sulfite and sulfate, through a series of oxidations [5,11]. Moreover, *L*-Cys is a source of endogenous SO<sub>2</sub> as well as a precursor for glutathione (GSH) [12]. Some enzymes in the network of *L*-Cys metabolism

\*Address correspondence to these authors at the Department of Pediatrics, Peking University First Hospital, Beijing, 100034, P. R. China; Tel: +8610-83573238; Fax: +8610-66551298; E-mail: junbaodu1@126.com  
Department of Physiology and Pathophysiology, Peking University Health Science Center, Beijing, 100191, China; Tel: +8610-82805222; E-mail: tangchaoshu@263.net.cn

play an essential role in the generation of sulfate, taurine and GSH in liver, including AAT, CDO, CSD and  $\gamma$ -glutamylcysteine synthetase (GCS, a key enzyme catalyzing *L*-Cys to GSH) [12]. The metabolism of *L*-Cys reveals a potential relationship between endogenous SO<sub>2</sub> and cellular redox status. For example, some researchers found over-dosed *L*-Cys could disturb the redox status in the human body [13] (Fig. 1).

Mitsuhashi *et al.* reported that activated neutrophils obtained from the inflamed peritoneal cavity spontaneously yielded sulfite in higher amounts than non-stimulated neutrophils isolated from the blood [14]. They further explained that sulfite production depended on the availability of PAPS [14]. Using an *in vitro* model of rat neutrophil activation induced by lipopolysaccharide, Mitsuhashi *et al.* demonstrated that oxidative stress by activated neutrophils could convert H<sub>2</sub>S to sulfite with the assistance of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase; in activated neutrophils, 15% H<sub>2</sub>S was converted to sulfite within 30 min [15] (Fig. 1).

Balazy *et al.* analyzed the headspace gas of incubation of porcine coronary arterial rings and cardiac muscle tissues in Krebs buffer [3]. They used gas chromatography–mass spectrometry to detect 2 gases: carbonyl sulfide and SO<sub>2</sub>. SO<sub>2</sub> formation was observed in the porcine coronary artery after incubation with calcium ionophore [3]. SO<sub>2</sub> may be produced by an intracellular thiol, and Balazy *et al.* also speculated that SO<sub>2</sub> could originate from the disproportion or oxidation of the very unstable molecule sulfur monoxide [3].

Humphries *et al.* confirmed that bovine aortic endothelial cells and smooth muscle cells could use Cys as a sulfate source [16]. On the basis of the abovementioned conclusions, Du *et al.* first measured endogenous SO<sub>2</sub> pathway in cardiovascular system, including SO<sub>2</sub> concentration in plasma and different tissues of Wistar rats and evaluated the distribution of AAT and its mRNA [17]. SO<sub>2</sub> concentration in rat plasma was 15.54±1.68  $\mu$ mol/L. Aortic tissue had the highest content of SO<sub>2</sub>, up to 5.55±0.35  $\mu$ mol/g protein, followed by (in  $\mu$ mol/g protein) pulmonary arteries (3.27±0.21), mesenteric arteries (2.67±0.17), tail arteries (2.50±0.20), and renal arteries (2.23±0.19) [17]. The activity of AAT of the renal arteries was higher than that in any of the other tissues they inspected [17]. Du *et al.* also assessed AAT mRNA expression in endothelial cells and vascular smooth muscle cells beneath the endothelial layer [17]. However, in 1977, because of the limitations of methodology, sulfite in normal human plasma and urine were not detectable, unless in cases of sulfur oxidase deficiency [18]. Later, Allena *et al.* gave the reference range for total serum sulfite: 0~9.85  $\mu$ mol/L in normal human beings by high-performance liquid chromatography with fluorescence detection [19]. In patients with acute pneumonia, Mitsuhashi *et al.* found the serum sulfite increased to 3.75±0.88  $\mu$ mol/L as compared with control subjects (1.23±0.48  $\mu$ mol/L) [20]. The authors also investigated serum level of sulfite in Wistar rats: the normal level was 1.3±0.23  $\mu$ mol/L [15]. Recently, Meng *et al.* demonstrated that the basal sulfite level of plasma in Wistar rat was 12.59±9.03  $\mu$ mol/L [21]. The latest research showed that endogenous SO<sub>2</sub> was mainly generated in endothelial cells of vascular tissues [22] in accordance with previous findings [17].

## TOXICOLOGICAL EFFECTS OF SO<sub>2</sub>

As a gaseous atmospheric toxin, SO<sub>2</sub> has been linked to various symptoms (e.g., cough and dyspnea) [23]. For example, SO<sub>2</sub> could produce pulmonary neutrophilic inflammation and aggravate cough [24]. Much research has suggested that SO<sub>2</sub> exposure could decrease heart rate variability and be related to cardiac dysrhythmia, which might be a potential mechanism responsible for cardiovascular disease morbidity and mortality [25-28]. In pre-existing asthma subjects, inhalation of SO<sub>2</sub> could exacerbate this disease, possibly by inducing asthma-related gene expression or regulating apoptosis-related genes in the lung [29-31]. In spontaneously hypertensive rats (SHRs), airway inflammation tended to be induced by SO<sub>2</sub> [32]. Epidemiological research involving more than 4 million visits to hospital emergency departments showed that exposure to ambient air pollution increased the susceptibility to adverse cardiovascular events among people with pre-existing cardiovascular and respiratory illnesses [33]. According to these investigations, subjects with pre-existing cardiopulmonary disease had greater SO<sub>2</sub> sensitivity in general. As well, large-artery endothelial functions could be impaired by exposure to air pollution (especially SO<sub>2</sub> and nitric oxide [NO]) in healthy young male volunteers [34].

Inhaling SO<sub>2</sub> can cause systemic oxidative damage [35]. Inhalation of SO<sub>2</sub> was found to lead to oxidative injury of cardiovascular, respiratory, digestive, reproductive, endocrine and nervous systems [36-41]. SO<sub>2</sub> inhaled by humans or mammals is readily hydrated to sulfurous acid, which subsequently dissociates to yield sulfite ions and bisulfite ions. The 2 ions exist in blood circulation, and sulfite ions can be oxidized to sulfate ions, which is, potentially, an essential process of modulating the level of sulfite *in vivo* [42]. SO<sub>2</sub> toxicity is sometimes present with respect to sulfite ions. The formation of sulfur- and oxygen-centered free radicals such as SO<sub>3</sub><sup>-</sup>, SO<sub>4</sub><sup>-</sup> and SO<sub>5</sub><sup>-</sup> contributes to SO<sub>2</sub>-induced toxicity during the oxidation of SO<sub>2</sub> derivatives [43]. As well, the change in the redox status of myocytes induced by SO<sub>2</sub> might be the etiologic cause of myocardial injury [44].

DNA damage caused by SO<sub>2</sub> and sulfite ions includes triggering an increase in the frequencies of chromosomal aberrations, sister chromatid exchanges, micronuclei formation and DNA–protein crosslinking in mammalian cells [36,45,46].

Furthermore, SO<sub>2</sub> could, alone or with other toxic agents, upregulate the expression of oncogenes (c-myc, H-ras, c-fos, c-jun and Ki-ras) and downregulate that of tumor suppressor genes (p53, p16 and Rb) in lung, liver and bronchial epithelial cells [47-50].

Zhang *et al.* proposed that glutamate dehydrogenase (GDH) could be inhibited by sulfite ions directly, which could give rise to sulfite oxidase deficiency in human infants [51]. The defect of this enzyme, sulfite oxidase, is attributed to neurologic abnormalities [18]. The inhibitory effect of a micromolar concentration of sulfite on mitochondrial GDH could induce a prompt increase in reactive oxygen species in Madin–Darby canine kidney cells, associated with depletion of intracellular adenosine triphosphate (ATP) [52].




Fig. (1). Endogenous generation and metabolism of sulfur dioxide.

## PHYSIOLOGICAL FUNCTIONS OF ENDOGENOUS SO<sub>2</sub> IN THE CARDIOVASCULAR SYSTEM

Meng *et al.* reported that short-term exposure to SO<sub>2</sub> (10–40 ppm) caused both a dose- and time-dependent reduction of blood pressure in Wistar rats [53]. The authors concluded that SO<sub>2</sub> is a systemic toxic agent to the cardiovascular system [53]. However, the physiological effects of endogenous SO<sub>2</sub> on the cardiovascular system have only been revealed recently.

Du *et al.* first found that with incubation with SO<sub>2</sub> derivatives (mixture of sodium bisulfite and sodium sulfite, 1:3 M/M in neutral solution), the isolated aortic rings of rats exhibited greater relaxant reactivity in a dose-dependent manner, but rings incubated with *L*-aspartate- $\beta$ -hydroxamate (HDX), the inhibitor of AAT, which suppressed the production of endogenous SO<sub>2</sub>, showed stronger vasoconstriction than that of the control group [54]. Moreover, this physiological vasorelaxant regulatory mechanism may be connected with the calcium (Ca<sup>2+</sup>) channel and ATP-sensitive

potassium (K<sub>ATP</sub>) channel [54]. Later, the authors determined that the endogenous SO<sub>2</sub> and its derivatives at a low concentration (25–100  $\mu$ mol/L) had a vasorelaxant effect *via* the SO<sub>2</sub>/AAT pathway, and the potential mechanism was not endothelium dependent but was related to the L-type Ca<sup>2+</sup> channel [17]. Meng *et al.* reported that the vasodilating function of SO<sub>2</sub> was independent of the synthesis of NO and the intact vascular endothelium but partially related to the signal transduction pathway of prostacyclin (PGI<sub>2</sub>)–adenylate cyclases (AC)–cAMP–protein kinase-A [55,56]. Recently, the vasorelaxant effect of SO<sub>2</sub> at basal and low concentrations was found to be endothelium dependent and accompanied by activation of NO synthase (NOS), while at a high concentration was endothelium independent and relied on the inhibition of the voltage-gated Ca<sup>2+</sup> channel with the opening of the K<sub>ATP</sub> and Ca<sup>2+</sup>-activated potassium (K<sup>+</sup>) channel [57,58]. The activation of NOS involved in this vasorelaxant mechanism contributing to the potential interaction of NO and SO<sub>2</sub> and the synergy of NO and endogenous SO<sub>2</sub> in vasoactivity has been shown [21]. In addition, SO<sub>2</sub> level in vascular tissue

could be increased by acetylcholine and decreased by noradrenaline [22], which further clarified the association of endogenous SO<sub>2</sub> and vasoactivity.

SO<sub>2</sub> derivatives could give rise to myocardial electrophysiological changes by inducing K<sup>+</sup>, Ca<sup>2+</sup> and sodium (Na<sup>+</sup>) currents and modulating voltage-gated K<sup>+</sup> channels, L-type Ca<sup>2+</sup> channels and voltage-gated Na<sup>+</sup> channels [59-61]. The channels shared the similar underlying mechanism, with possible involvement of the switch to the redox status of amino acid residues of these channel protein subunits [59-61]. SO<sub>2</sub> could also inhibit both inward and outward Na<sup>+</sup>-Ca<sup>2+</sup> exchange currents in myocytes, thus leading to an increase in myocardial intracellular free Ca<sup>2+</sup> concentration [62].

### **PATHOPHYSIOLOGICAL EFFECTS OF ENDOGENOUS SO<sub>2</sub> ON THE CARDIOVASCULAR SYSTEM**

Little is known about the pathophysiological significance of endogenous SO<sub>2</sub> in cardiovascular diseases other than the toxicological outcomes of exogenous SO<sub>2</sub>.

Zhao *et al.* first reported that the systemic blood pressure of 5-week SHR was higher than that of Wistar Kyoto rats, whereas the plasma SO<sub>2</sub> content of SHR was decreased by 44% as compared with the controls [63]. With SO<sub>2</sub> derivatives treatment, the systolic blood pressure of SHR decreased significantly as compared with the untreated group. As well, the ratio of media to lumen radius, media pressure and the proliferative index of smooth muscle cells in the aorta of SHR treated with SO<sub>2</sub> derivatives were lower than those of untreated rats [64, 65]. Thus, the decreased endogenous SO<sub>2</sub> production might be involved in the process of hypertension.

Pulmonary hypertension (PH) is characterized by an elevation in mean pulmonary arterial pressure and pulmonary vascular remodeling. The latter remodeling consists of hypertrophy and hyperplasia of various cells, together with accumulation of the extracellular matrix [66]. Sun *et al.* found that rats under hypoxic conditions exhibited significantly decreased SO<sub>2</sub> levels in plasma and lung tissue, with increased pulmonary artery pressure, pulmonary vascular remodeling and vascular inflammation [67]. This finding implied that the development of hypoxic PH was accompanied by the downregulation of endogenous SO<sub>2</sub> concentration. Tian *et al.* discovered that SO<sub>2</sub> derivatives could significantly lower mean pulmonary arterial pressure and systolic pulmonary arterial pressure of hypoxic pulmonary hypertensive rats, with no obvious effect on diastolic pulmonary arterial pressure [68]. As well, SO<sub>2</sub> and its derivatives could alleviate pulmonary vascular remodeling in hypoxic PH by inhibiting collagen type I and III agglomeration in vascular walls [69] and by inhibiting vascular smooth muscle cell proliferation, possibly by inactivating the extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway [67]. Inflammation is involved in hypoxic PH [70]. Apart from preventing pulmonary vascular remodeling, SO<sub>2</sub> could downregulate the expression of the 2 vital inflammation factors, nuclear factor-kappa B (NF-κB) and intercellular adhesion molecule-1 (ICAM-1) [71]. This result suggested the protective part SO<sub>2</sub> plays in regulating inflammation in experimental hypoxic PH [71].

SO<sub>2</sub> inhalation was found to decrease activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in several organs, weaken catalase (CAT) activities in liver and reduce GSH content, which suggests that SO<sub>2</sub> causes systemic oxidative damage [35]. However, Jin *et al.* discovered in a monocrotaline (MCT)-treated rat model that SO<sub>2</sub> derivatives could improve the activities of antioxidative enzymes, including SOD, GSH-Px and CAT, whereas the activities of these enzymes were decreased when endogenous SO<sub>2</sub> was inhibited by HDX [72]. This finding indicated that endogenous SO<sub>2</sub> could enhance the antioxidative effect in MCT-induced oxidative stress [72]. The authors also found that SO<sub>2</sub> alleviated structural remodeling in the small pulmonary artery and improved hemodynamic status in MCT-induced PH [72]. They concluded that the SO<sub>2</sub>/AAT pathway may participate the protection process in MCT-induced PH [72].

The formation of oxygen-derived free radicals is responsible for the cytotoxic process during ischemia. Reperfusion of the myocardium in several aspects and the peroxidation of lipid components of cellular and mitochondrial membranes is the main cellular damage during myocardial infarction [73]. Zhang *et al.* evaluated the role of SO<sub>2</sub> in isolated rat heart models of ischemia and reperfusion [74]. During reperfusion, inhibiting the generation of endogenous SO<sub>2</sub> reduced the permeability of the myocardial cell membrane and the production of myocardial malondialdehyde, a product of lipid peroxidation, and elevated the GSH content of myocardium [74]. This discovery implied that myocardial injury *via* SO<sub>2</sub> may be associated with increased lipid peroxidation and decreased GSH in the myocardium [74].

### **CONCLUSIONS AND PERSPECTIVES**

In the 1980s, the era of “gas biology” commenced with the profound understanding of NO, but NO is not the only biologically active gas in the human body. Carbon monoxide (CO) and, more recently, H<sub>2</sub>S, have been shown to have similar significance [75, 76]. The concept of the “gaseous signal family” was put forward. The 3 members carry out their functions individually and in a “cross-talk” manner [75,76]. Whether SO<sub>2</sub> should be recognized as a gaseous transmitter depends more on its physiological and pathophysiological effects in regulating the cardiovascular system than its toxicological influences on human health with abnormal atmospheric concentrations. SO<sub>2</sub> and H<sub>2</sub>S share the same endogenous source, namely SAAs [5,11], and the 2 gases can transform into each other (or their derivatives) *via* several biochemical reactions [5,11,15]. We suggest that the relationship between SO<sub>2</sub> and H<sub>2</sub>S may be a key factor linking SO<sub>2</sub> and gaseous signals. As well, the synergistic vasorelaxant function of SO<sub>2</sub> and NO is another path to combine SO<sub>2</sub> with gaseous signal family network.

Studies of SO<sub>2</sub> are not as simple as those of H<sub>2</sub>S because AAT is probably not a specific enzyme catalyzing only the reaction of SO<sub>2</sub> generation. AAT has a major role in various metabolisms (e.g., aspartate biosynthesis *via* transamination of oxaloacetate by glutamate) and is also indirectly connected to the urea cycle and tricarboxylic acid cycle [77]. Multiple factors should therefore be taken into consideration when its inhibitor HDX is used in research. However, this

complication of SO<sub>2</sub> existing in organisms indicates that its function *in vivo* results from its chemical and physical properties as a gaseous molecule and from its network-like interaction with the body energy, protein and inorganic salts metabolism. A tiny alteration in its level might give rise to a “butterfly effect” in the body function.

Drugs designed according to the biological activity of NO have revolutionized the therapy of cardiovascular diseases. Many functions of H<sub>2</sub>S have been revealed in the cardiovascular system [78-80], and a new water-soluble H<sub>2</sub>S-releasing molecule, GYY4137, was recently reported to have potential clinical significance in the cardiovascular system [81]. Although more unknowns about SO<sub>2</sub> are waiting to be elucidated in further explorations, the results obtained thus far suggest the novel role of SO<sub>2</sub> in modulating the cardiovascular system and provide a basis for new treatments for cardiovascular diseases.

#### ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (30630031, 30821001 and 30801251), the Key Program of Science and Technology, Ministry of Education, China (307001) and the Major Basic Research Program of China (2006CB503807).

#### REFERENCES

- Manahan, S. E. *Environmental Chemistry*, 5<sup>th</sup> ed.; Lewis Publishers: Michigan, **1991**.
- Komarnisky, L.A.; Christopherson, R.J.; Basu, T.K. Sulfur: its clinical and toxicologic aspects. *Nutrition*, **2003**, *19*, 54-61.
- Balazy, M.; Abu-Yousef, I.A.; Harpp, D.N.; Park, J. Identification of carbonyl sulfide and sulfur dioxide in porcine coronary artery by gas chromatography/mass spectrometry, possible relevance to EDHF. *Biochem. Biophys. Res. Commun.*, **2003**, *331*, 728-734.
- Stipanuk, M.H. Metabolism of sulfur-containing amino acids. *Annu. Rev. Nutr.*, **1986**, *6*, 179-209.
- Stipanuk, M.H. Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. *Annu. Rev. Nutr.*, **2004**, *24*, 539-577.
- Brosnan, J.T.; Brosnan, M.E. The sulfur-containing amino acids: an overview. *J. Nutr.*, **2006**, *136*, 1636S-1640S.
- Singer, T.P.; Kearney, E.B. Intermediary metabolism of L-cysteinesulfinic acid in animal tissues. *Arch. Biochem. Biophys.*, **1956**, *61*, 397-409.
- Sardesai, V.M. Molybdenum: an essential trace element. *Nutr. Clin. Pract.*, **1993**, *8*, 277-81.
- Griffith, O.W. Cysteinesulfinate metabolism: altered partitioning between transamination and decarboxylation following administration of β-methyleneaspartate. *J. Biol. Chem.*, **1983**, *258*, 1591-1598.
- Shoveller, A.K.; Stoll, B.; Ball, R.O.; Burrin, D.G. Nutritional and functional importance of intestinal sulfur amino acid metabolism. *J. Nutr.*, **2005**, *135*, 1609-1612.
- Beauchamp, R.O.Jr.; Bus, J.S.; Popp, J.A.; Boreiko, C.J.; Andjelkovich, D.A. A critical review of the literature on hydrogen sulfide toxicity. *Crit. Rev. Toxicol.*, **1984**, *13*, 25-97.
- Stipanuk, M.H.; Londono, M.; Lee, J.I.; Hu, M.; Yu, A.F. Enzymes and metabolites of cysteine metabolism in nonhepatic tissues of rats show little response to changes in dietary protein or sulfur amino acid levels. *J. Nutr.*, **2002**, *132*, 3369-3378.
- Dilger, R.N.; Baker, D.H. Excess dietary L-cysteine causes lethal metabolic acidosis in chicks. *J. Nutr.*, **2008**, *138*: 1628-1633.
- Mitsuhashi, H.; Ota, F.; Ikeuchi, K.; Kaneko, Y.; Kuroiwa, T.; Ueki, K.; Tsukada, Y.; Nojima, Y. Sulfite is generated from PAPS by activated neutrophils. *Tohoku. J. Exp. Med.*, **2002**, *198*, 125-132.
- Mitsuhashi, H.; Yamashita, S.; Ikeuchi, H.; Kuroiwa, T.; Kaneko, Y.; Hiromura, K.; Ueki, K.; Nojima, Y. Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. *Shock*, **2005**, *24*, 529-534.
- Humphries, D.E.; Silbert, C.K.; Silbert, J.E. Sulphation by cultured cells: cysteine, cysteinesulphinic acid and sulphite as sources for proteoglycan sulphate. *Biochem. J.*, **1988**, *252*, 305-308.
- Du, S.X.; Jin, H.F.; Bu, D.F.; Zhao, X.; Geng, B.; Tang, C.S.; Du, J.B. Endogenously generated sulfur dioxide and its vasorelaxant effect in rats. *Acta Pharmacol. Sin.*, **2008**, *29*, 923-930.
- Shih, V.E.; Abroms, I.F.; Johnson, J.L.; Carney, M.; Mandell, R.; Robb, R.M.; Cloherty, J.P.; Rajagopalan, K.V. Sulfite oxidase deficiency: biochemical and clinical investigations of a hereditary metabolic disorder in sulfur metabolism. *N. Engl. J. Med.*, **1977**, *297*, 1022-1028.
- Ji, A.J.; Savon, S.R.; Jacobson, D.W. Determination of total serum sulfite by HPLC with fluorescence detection. *Clin. Chem.*, **1995**, *41*, 897-903.
- Mitsuhashi, H.; Ikeuchi, H.; Yamashita, S.; Kuroiwa, T.; Kaneko, Y.; Hiromura, K.; Ueki, K.; Nojima, Y. Increased levels of serum sulfite in patients with acute pneumonia. *Shock*, **2004**, *21*, 99-102.
- Li, J.; Meng, Z. The role of sulfur dioxide as an endogenous gaseous vasoactive factor in synergy with nitric oxide. *Nitric Oxide*, **2009**, *20*, 166-174.
- Meng, Z.; Li, J.; Zhang, Q.; Bai, W.; Yang, Z.; Zhao, Y.; Wang, F. Vasodilator effect of gaseous sulfur dioxide and regulation of its level by Ach in rat vascular tissues. *Inhal. Toxicol.*, **2009**, *21*, 1223-1228.
- Chen, T.M.; Gokhale, J.; Shofer, S.; Kuschner, W.G. Outdoor air pollution: nitrogen dioxide, sulfur dioxide, and carbon monoxide health effects. *Am. J. Med. Sci.*, **2007**, *333*, 249-256.
- McLeod, R.L.; Jia, Y.; McHugh, N.A.; Fernandez, X.; Mingo, G.G.; Wang, X.; Parra, L.E.; Chen, J.; Brown, D.; Bolser, D.C.; Kreutner, W.; Hey, J.A. Sulfur-dioxide exposure increases TRPV1-mediated responses in nodose ganglia cells and augments cough in guinea pigs. *Pulm. Pharmacol. Ther.*, **2007**, *20*, 750-757.
- Min, K.B.; Min, J.Y.; Cho, S.I.; Paek, D. The relationship between air pollutants and heart-rate variability among community residents in Korea. *Inhal. Toxicol.*, **2008**, *20*, 435-444.
- Min, J.Y.; Min, K.B.; Cho, S.I.; Paek, D. Combined effect of cigarette smoking and sulfur dioxide on heart rate variability. *Int. J. Cardiol.*, **2009**, *133*, 119-121.
- Liao, D.; Duan, Y.; Whitsel, E.A.; Zheng, Z.J.; Heiss, G.; Chinchilli, V.M.; Lin, H.M. Association of higher levels of ambient criteria pollutants with impaired cardiac autonomic control: a population-based study. *Am. J. Epidemiol.*, **2004**, *159*, 768-777.
- Koken, P.J.; Piver, W.T.; Ye, F.; Elixhauser, A.; Olsen, L.M.; Portier, C.J. Temperature, air pollution, and hospitalization for cardiovascular diseases among elderly people in Denver. *Environ. Health Perspect.*, **2003**, *111*, 1312-1317.
- Li, R.; Meng, Z.; Xie, J. Effects of sulfur dioxide derivatives on four asthma-related gene expressions in human bronchial epithelial cells. *Toxicol. Lett.*, **2007**, *175*, 71-81.
- Li, R.; Meng, Z.; Xie, J. Effects of sulfur dioxide on the expressions of EGF, EGFR, and COX-2 in airway of asthmatic rats. *Arch. Environ. Contam. Toxicol.*, **2008**, *54*, 748-757.
- Xie, J.; Li, R.; Fan, R.; Meng, Z. Effects of sulfur dioxide on expressions of p53, bax and bcl-2 in lungs of asthmatic rats. *Inhal. Toxicol.*, **2009**, *21*, 952-957.
- Kodavanti, U.P.; Schladweiler, M.C.; Ledbetter, A.D.; Ortuno, R.V.; Suffia, M.; Evansky, P.; Richards, J.H.; Jaskot, R.H.; Thomas, R.; Karoly, E.; Huang, Y.C.; Costa, D.L.; Gilmour, P.S.; Pinkerton, K.E. The spontaneously hypertensive rat: an experimental model of sulfur dioxide-induced airways disease. *Toxicol. Sci.*, **2006**, *94*, 193-205.
- Peel, J.L.; Metzger, K.B.; Klein, M.; Flanders, W.D.; Mulholland, J.A.; Tolbert, P.E. Ambient air pollution and cardiovascular emergency department visits in potentially sensitive groups. *Am. J. Epidemiol.*, **2007**, *165*, 625-633.

- [34] Briet, M.; Collin, C.; Laurent, S.; Tan, A.; Azizi, M.; Agharazii, M.; Jeunemaitre, X.; Alhenc-Gelas, F.; Boutouyrie, P. *Hypertension*, **2007**, *50*, 970-976.
- [35] Meng, Z. Oxidative damage of sulfur dioxide on various organs of mice: sulfur dioxide is a systemic oxidative damage agent. *Inhal. Toxicol.*, **2003**, *15*, 181-195.
- [36] Xie, J.; Fan, R.; Meng, Z. Protein oxidation and DNA-protein crosslink induced by sulfur dioxide in lungs, livers, and hearts from mice. *Inhal. Toxicol.*, **2007**, *19*, 759-765.
- [37] Meng, Z.; Qin, G.; Zhang, B.; Geng, H.; Bai, Q.; Bai, W.; Liu, C. Oxidative damage of sulfur dioxide inhalation on lungs and hearts of mice. *Environ. Res.*, **2003**, *93*, 285-292.
- [38] Meng, Z.; Zhang, B.; Bai, J.; Geng, H.; Liu, C. Oxidative damage of sulfur dioxide inhalation on stomachs and intestines of mice. *Inhal. Toxicol.*, **2003**, *15*, 397-410.
- [39] Meng, Z.; Bai, W. Oxidation damage of sulfur dioxide on testicles of mice. *Environ. Res.*, **2004**, *96*, 298-304.
- [40] Agar, A.; Küçükataay, V.; Yargicoglu, P.; Bilmen, S.; Gümüşlü, S.; Yücel, G. Effect of sulfur dioxide inhalation on erythrocyte antioxidant status and lipid peroxidation in experimental diabetes. *Diabetes Metab.*, **2000**, *26*, 140-144.
- [41] Meng, Z.; Zhang, B. Oxidative damage of sulfur dioxide inhalation on brains and livers of mice. *Environ. Toxicol. Pharmacol.*, **2003**, *13*, 1-8.
- [42] Pettit, F.H.; Lyon, D.; Brown, J.R.; Shive, W. Evidence for sulfite as an essential metabolite for human peripheral lymphocytes. *Biochem. Biophys. Res. Commun.*, **1991**, *179*, 611-614.
- [43] Shi, X. Generation of  $\text{SO}_3^-$  and OH radicals in  $\text{SO}_3^{2-}$  reactions with inorganic environmental pollutants and its implications to  $\text{SO}_3^{2-}$  toxicity. *J. Inorg. Biochem.*, **1994**, *56*, 155-165.
- [44] Wei, H.; Meng, Z. Enhancing effects of diethylthiocarbamate on increase of sodium channel by sulfur dioxide derivatives in ventricular myocytes. *Cell Biol. Int.*, **2008**, *32*, 1143-1149.
- [45] Meng, Z.; Qin, G.; Zhang, B.; Bai, J. DNA damaging effects of sulfur dioxide derivatives in cells from various organs of mice. *Mutagenesis*, **2004**, *19*, 465-468.
- [46] Meng, Z.; Qin, G.; Zhang, B. DNA damage in mice treated with sulfur dioxide by inhalation. *Environ. Mol. Mutagen.*, **2005**, *46*, 150-155.
- [47] Qin, G.; Meng, Z. Expression of oncogenes and tumor suppressor genes in lungs of rats exposed to sulfur dioxide and benzo(a)pyrene. *Inhal. Toxicol.*, **2010**, *22*, 322-329.
- [48] Bai, J.; Meng, Z. Effect of sulfur dioxide on expression of proto-oncogenes and tumor suppressor genes from rats. *Environ. Toxicol.*, **2010**, *25*, 272-283.
- [49] Qin, G.; Meng, Z. Sulfur dioxide and benzo(a)pyrene modulates CYP1A and tumor-related gene expression in rat liver. *Environ. Toxicol.*, **2010**, *25*, 169-179.
- [50] Qin, G.; Meng, Z. Effects of sulfur dioxide derivatives on expression of oncogenes and tumor suppressor genes in human bronchial epithelial cells. *Food Chem. Toxicol.*, **2009**, *47*, 734-744.
- [51] Zhang, X.; Vincent, A.S.; Halliwell, B.; Wong, K.P. A mechanism of sulfite neurotoxicity: direct inhibition of glutamate dehydrogenase. *J. Biol. Chem.*, **2004**, *279*, 43035-43045.
- [52] Vincent, A.S.; Lim, B.G.; Tan, J.; Whiteman, M.; Cheung, N.S.; Halliwell, B.; Wong, K.P. Sulfite-mediated oxidative stress in kidney cells. *Kidney Int.*, **2004**, *65*, 393-402.
- [53] Meng, Z.; Geng, H.; Bai, J.; Yan, G. Blood pressure of rats lowered by sulfur dioxide and its derivatives. *Inhal. Toxicol.*, **2003**, *15*, 951-959.
- [54] Du, S.X.; Zhang, C.Y.; Jin, H.F.; Du, J.B.; Tang, C.S. Vasorelaxant effect of sulfur dioxide derivatives on isolated aortic rings of rats and its mechanism. *J. Peking. Univ. (Health Sc.)*, **2006**, *38*, 581-585.
- [55] Meng, Z.; Li, Y.; Li, J. Vasodilatation of sulfur dioxide derivatives and signal transduction. *Arch. Biochem. Biophys.*, **2007**, *467*, 291-296.
- [56] Meng, Z.; Zhang, H. The vasodilator effect and its mechanism of sulfur dioxide-derivatives on isolated aortic rings of rats. *Inhal. Toxicol.*, **2007**, *19*, 979-986.
- [57] Wang, Y.K.; Ren, A.J.; Yang, X.Q.; Wang, L.G.; Rong, W.F.; Tang, C.S.; Yuan, W.J.; Lin, L. Sulfur dioxide relaxes rat aorta by endothelium-dependent and -independent mechanisms. *Physiol. Res.*, **2009**, *58*, 521-527.
- [58] Zhang, Q.; Meng, Z. The vasodilator mechanism of sulfur dioxide on isolated aortic rings of rats: Involvement of the  $\text{K}^+$  and  $\text{Ca}^{2+}$  channels. *Eur. J. Pharmacol.*, **2009**, *602*, 117-123.
- [59] Nie, A.; Meng, Z. Sulfur dioxide derivative modulation of potassium channels in rat ventricular myocytes. *Arch. Biochem. Biophys.*, **2005**, *442*, 187-195.
- [60] Nie, A.; Meng, Z. Modulation of L-type calcium current in rat cardiac myocytes by sulfur dioxide derivatives. *Food Chem. Toxicol.*, **2006**, *44*, 355-363.
- [61] Nie, A.; Meng, Z. Study of the interaction of sulfur dioxide derivative with cardiac sodium channel. *Biochim. Biophys. Acta*, **2005**, *1718*, 67-73.
- [62] Nie, A.; Meng, Z. Sulfur dioxide derivatives modulate Na/Ca exchange currents and cytosolic  $[\text{Ca}^{2+}]_i$  in rat myocytes. *Biochem. Biophys. Res. Commun.*, **2007**, *358*, 879-884.
- [63] Zhao, X.; Jin, H.F.; Tang, C.S.; Du, J.B. Effect of sulfur dioxide on vascular collagen remodeling in spontaneously hypertensive rats. *Zhonghua Er Ke Za Zhi.*, **2008**, *46*, 905-908.
- [64] Du, S.X.; Jin, H.F.; Liang, Y.F.; Zhao, X.; Wei, H.L.; Wang, L.; Du, J.B.; Tang, C.S. Influence of sulfur dioxide and its derivatives on rats' blood pressure. *J. Appl. Clin. Pediatr.*, **2008**, *23*, 22-24.
- [65] Zhao, X.; Jin, H.F.; Du, S.X.; Tang, C.S.; Du, J.B. The effect of sulfur dioxide on blood pressure and aortic structure of spontaneously hypertensive rat. *Chin. Pharmacol. Bull.*, **2008**, *24*, 327-330.
- [66] Tuder, R.M.; Marecki, J.C.; Richter, A.; Fijalkowska, I.; Flores, S. Pathology of Pulmonary Hypertension. *Clin. Chest. Med.*, **2007**, *28*, 23-42, vii.
- [67] Sun, Y.; Tian, Y.; Prabha, M.; Liu, D.; Chen, S.; Zhang, R.; Liu, X.; Tang, C.; Tang, X.; Jin, H.; Du, J. Effects of sulfur dioxide on hypoxic pulmonary vascular structural remodeling. *Lab. Invest.*, **2010**, *90*, 68-82.
- [68] Tian, Y.; Wang, L.; Jin, H.F.; Tang, C.S.; Du, J.B. Effect of exogenous sulfur dioxide on pulmonary artery pressure of rats with hypoxic pulmonary hypertension. *J. Appl. Clin. Pediatr.*, **2007**, *22*, 1729-1730.
- [69] Prabha, M.; Tian, Y.; Jin, H.F.; Liu, X.Q.; Tang, C.S.; Du, J.B. Effects of sulphur dioxide on pulmonary artery collagen accumulation of rats with hypoxic pulmonary hypertension. *J. Appl. Clin. Pediatr.*, **2008**, *23*, 771-773.
- [70] Dorfmueller, P.; Perros, F.; Balabanian, K.; Humbert, M. Inflammation in pulmonary arterial hypertension. *Eur. Respir. J.*, **2003**, *22*, 358-363.
- [71] Tian, Y.; Prabha, M.; Liu, X.Q.; Tang, C.S.; Du, J.B. Effect of sulfur dioxide on small pulmonary artery endothelial cell inflammation reaction of hypoxic pulmonary hypertensive rats. *J. Appl. Clin. Pediatr.*, **2008**, *23*, 985-987.
- [72] Jin, H.F.; Du, S.X.; Zhao, X.; Wei, H.L.; Wang, Y.F.; Liang, Y.; Tang, C.S.; Du, J.B. Effects of endogenous sulfur dioxide on monocrotaline-induced pulmonary hypertension in rats. *Acta Pharmacol. Sin.*, **2008**, *29*, 1157-1166.
- [73] Maupoil, V.; Rochette, L. Evaluation of free radical and lipid peroxide formation during global ischemia and reperfusion in isolated perfused rat heart. *Cardiovasc. Drugs. Ther.*, **1988**, *2*, 615-621.
- [74] Zhang, S.; Du, J.; Jin, H.; Li, W.; Liang, Y.; Geng, B.; Li, S.; Zhang, C.; Tang, C. Endogenous sulfur dioxide aggravates myocardial injury in isolated rat heart with ischemia and reperfusion. *Transplantation*, **2009**, *87*, 517-524.
- [75] Zhang, Q.; Du, J.; Zhou, W.; Yan, H.; Tang, C.; Zhang, C. Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. *Biochem. Biophys. Res. Commun.*, **2004**, *317*, 30-37.
- [76] Li, L.; Moore, P.K. An overview of the biological significance of endogenous gases: new roles for old molecules. *Biochem. Soc. Trans.*, **2007**, *35*, 1138-1141.
- [77] Garrett, R.H.; Grisham, C.M. *Biochemistry*, 2<sup>nd</sup> ed.; Harcourt: Orlando, **1999**.

- [78] Zhao, X.; Zhang, L.K.; Zhang, C.Y.; Zeng, X.J.; Yan, H.; Jin, H.F.; Tang, C.S.; Du, J.B. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. *Hypertens. Res.*, **2008**, *31*, 1619-1630.
- [79] Laggner, H.; Hermann, M.; Esterbauer, H.; Muellner, M.K.; Exner, M.; Gmeiner, B.M.; Kapiotis, S. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. *J. Hypertens.*, **2007**, *25*, 2100-2104.
- [80] Li, X.; Du, J.; Jin, H.; Geng, B.; Tang, C. Sodium hydrosulfide alleviates pulmonary artery collagen remodeling in rats with high pulmonary blood flow. *Heart Vessels*, **2008**, *23*, 409-419.
- [81] Li, L.; Whiteman, M.; Guan, Y.Y.; Neo, K.L.; Cheng, Y.; Lee, S.W.; Zhao, Y.; Baskar, R.; Tan, C.H.; Moore, P.K. Characterization of a Novel, Water-Soluble Hydrogen Sulfide-Releasing Molecule (GYY4137): New Insights Into the Biology of Hydrogen Sulfide. *Circulation*, **2008**, *117*, 2351-2360.

---

Received: April 28, 2010

Revised: July 04, 2010

Accepted: July 10, 2010